Literature DB >> 8694860

Lipocortin 1 and the control of cPLA2 activity in A549 cells. Glucocorticoids block EGF stimulation of cPLA2 phosphorylation.

J D Croxtall1, Q Choudhury, S Newman, R J Flower.   

Abstract

Epidermal growth factor (EGF) rapidly stimulates the release of arachidonic acid in A549 cells by a mechanism that is sensitive to pertussis toxin [1]. We show that EGF treatment of A549 cells stimulates phosphorylation of cytosolic phospholipase A2 (cPLA2) through a mechanism that is similarly inhibited by pertussis toxin. The level of cPLA2 expression is, apparently, not changed during this period. Pretreatment of cells with dexamethasone (10-100 nM) for 3 hr prevents this activation of cPLA2 by EFG, without changing the level of cPLA21 expression. The effect of dexamethasone is reversed in the presence of the neutralizing antilipocortin Mab 1A but not by the nonneutralizing antilipocortin 1 control Mab 1B. This strongly suggests that lipocortin 1 mediates the effect of dexamethasone by inhibiting activation of cPLA2. This concept is supported by the fact that a peptide Lc13-25 (10-200 micrograms/mL), derived from the N-terminus of lipocortin 1, also inhibits activation of cPLA2 by EGF in these cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8694860     DOI: 10.1016/0006-2952(95)02442-5

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

1.  Translocation of annexin I from cellular membrane to the nuclear membrane in human esophageal squamous cell carcinoma.

Authors:  Yu Liu; Hui-Xin Wang; Ning Lu; You-Sheng Mao; Fang Liu; Ying Wang; Hai-Rong Zhang; Kun Wang; Min Wu; Xiao-Hang Zhao
Journal:  World J Gastroenterol       Date:  2003-04       Impact factor: 5.742

2.  The regulation of prostaglandin output from term intact fetal membranes by anti-inflammatory cytokines.

Authors:  N L Brown; S A Alvi; M G Elder; P R Bennett; M H Sullivan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 3.  General molecular biology and architecture of nuclear receptors.

Authors:  Michal Pawlak; Philippe Lefebvre; Bart Staels
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

4.  Annexin A1 regulates intestinal mucosal injury, inflammation, and repair.

Authors:  Brian A Babbin; Mike G Laukoetter; Porfirio Nava; Stefan Koch; Winston Y Lee; Christopher T Capaldo; Eric Peatman; Eric A Severson; Roderick J Flower; Mauro Perretti; Charles A Parkos; Asma Nusrat
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

5.  Investigation into the involvement of phospholipases A(2) and MAP kinases in modulation of AA release and cell growth in A549 cells.

Authors:  Q G Choudhury; D T McKay; R J Flower; J D Croxtall
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

6.  Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays.

Authors:  H Zhu; J P Cong; G Mamtora; T Gingeras; T Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

7.  Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism.

Authors:  J D Croxtall; Q Choudhury; R J Flower
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

8.  Nuclear signalling by rac GTPase: essential role of phospholipase A2.

Authors:  B C Kim; J H Kim
Journal:  Biochem J       Date:  1997-09-01       Impact factor: 3.857

9.  The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.

Authors:  R Newton; L Cambridge; L A Hart; D A Stevens; M A Lindsay; P J Barnes
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

Review 10.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.

Authors:  Renato Malcher-Lopes; Alier Franco; Jeffrey G Tasker
Journal:  Eur J Pharmacol       Date:  2008-01-31       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.